Starting HAART: When to Take the First Step?
20 July, 2010
- Steven Deeks (United States) Professor of Medicine, University of California, San Francisco (UCSF)
- Peter Mugyenyi (Uganda) Director and Founder, Joint Clinical Research Center Kampala, Uganda
- Mark Harrington (United States) Executive Director of the Treatement Action Group (TAG)
- Ambassador Eric Goosby (United States) U.S. Global AIDS Coordinator, U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)
Recent guidelines are all recommending that HIV treatment be started at a higher CD4 count because of issues such as the ongoing damage caused by HIV itself, and prevention of transmission. Issues in long-term treatment, such as potential side effects, the development of resistance, the cost and sustainability of programmes in resource-poor settings, are some of the potential problems for such a strategy. This session discussed the pros and cons of early initiation and highlighted areas of controversy and agreement.